CINC CINCOR PHARMA INC

CinCor Pharma to Participate at Upcoming September Investor Conferences

CinCor Pharma to Participate at Upcoming September Investor Conferences

WALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the following investor conferences: Citi's 17th Annual BioPharma Conference taking place September 6 - 8, 2022 in Boston, MA and Morgan Stanley’s 20th Annual Healthcare Conference, taking place September 12 - 13, 2022 in New York, NY.

Company management will also present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 3:45 PM ET in Boston, MA. A link to the live webcast will be available at . An archived replay of the presentation will be available for 90 days at .

The CinCor management team will participate in investor meetings during each of these events. Investors interested in meeting with CinCor at the conference should contact their respective event representative.

About CinCor

CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

Contacts:Investors:
Terry CoelhoBob Yedid
CinCor Pharma, Inc.LifeSci Advisors
EVP, CFO and CBDO

                                                        

 



EN
31/08/2022

Underlying

CINCCINCOR PHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CINCOR PHARMA INC

 PRESS RELEASE
Free
CINC CINCOR PHARMA I...

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting...

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective aldosterone synthase inhibitor. On February 17, 2023, the Company received the official meeting...

February 21, 2023 1 EN
 PRESS RELEASE
Free
CINC CINCOR PHARMA I...

CinCor Pharma to be Acquired by AstraZeneca

CinCor Pharma to be Acquired by AstraZeneca WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved....

January 9, 2023 1 EN
 PRESS RELEASE
Free
CINC CINCOR PHARMA I...

CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating...

CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population (nominal p-value = 0.001) Safety profile and tolerability consistent with BrigHtn Phase 2 data; no patient discontinued due to treatment-related adverse ...

November 28, 2022 1 EN
 PRESS RELEASE
Free
CINC CINCOR PHARMA I...

CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI In...

CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November: Event:Piper Sandler 34th Annual Healthcare ConferenceDate:November 29 – December 1, 2022Location:Lotte New York Palace in New York, New YorkPresentation:Tuesday, November 29, 2022 at 1:30pm ESTWebcast:  Event:Evercore ISI 5th Annual HealthCONx ConferenceDate:November 30 – December 1, 2022Location:VirtualPresentatio...

November 22, 2022 1 EN
 PRESS RELEASE
Free
CINC CINCOR PHARMA I...

CinCor Pharma to Present at Upcoming Jefferies London Healthcare Confe...

CinCor Pharma to Present at Upcoming Jefferies London Healthcare Conference WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking place on November 15-17, 2022 in London, United Kingdom. The presentation information is below: Jefferies London Healthcare ConferencePresentation:Wednesday, November 16, 2022 at 5 PM GMTLocation:Track 2 – Room, Adelphi 2, Ground Level at the Waldorf Hilton The CinCor management team will participate in one-on-one invest...

November 9, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch